Overview
Checkpoint Blockade in the Adjuvant and Neoadjuvant Settings: Key Considerations for the Surgical Oncologist
Virtual Tumor Board
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
A multidisciplinary panel of faculty discuss the use of neoadjuvant and adjuvant immunotherapy for esophageal and gastric cancers in this recorded virtual tumor board. Throughout the case discussions, faculty discuss how to properly incorporate immunotherapies into care plans based on the latest clinical trial data and recommendations. The faculty also highlight the role of biomarkers in identifying eligible patients and ongoing clinical trials that will further impact the use of immunotherapies in gastroesophageal cancers.
This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with gastric and esophageal cancer.
The introduction of immunotherapies has paved the way for new standards of care in the treatment of gastroesophageal cancers. Surgical oncologists must weigh the use of immunotherapy as they assess how to improve recurrence free survival in patients with resectable disease. This activity offers guidance and perspectives from expert faculty to help surgical oncologists integrate immunotherapies into neoadjuvant and adjuvant approaches. Additionally, the faculty provide insights into the future for immunotherapies, based on ongoing clinical trials.
At the conclusion of this activity, participants should be able to:
• Describe the mechanistic rationale for the role of immunotherapies in earlier stage gastric and esophageal cancer
• Summarize available and ongoing clinical trial data on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable gastric and esophageal cancers
• Translate the latest clinical trial data to identify appropriate patients with significant recurrence risk who may benefit from approved or emerging uses of neoadjuvant or adjuvant immunotherapy
• Assess emerging biomarkers for ICIs in the early disease setting and their potential predictive role in assessing long term benefits
• Describe the mechanistic rationale for the role of immunotherapies in earlier stage gastric and esophageal cancer
• Summarize available and ongoing clinical trial data on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable gastric and esophageal cancers
• Translate the latest clinical trial data to identify appropriate patients with significant recurrence risk who may benefit from approved or emerging uses of neoadjuvant or adjuvant immunotherapy
• Assess emerging biomarkers for ICIs in the early disease setting and their potential predictive role in assessing long term benefits
Sponsored by the Society of Surgical Oncology (SSO) and the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Merck & Co.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.
G. Travis Clifton, MD (Moderator)
Brooke Army Medical Center
Brooke Army Medical Center
Mihir M. Shah, MD (Panelist)
Emory University / Winship Cancer Institute
Salma Jabbour, MD (Panelist)
Rutgers Cancer Institute of New Jersey
Howard Hochster, MD (Panelist)
Rutgers Cancer Institute of New Jersey
Onkar Khullar, MD, MSc (Panelist)
Emory University / Winship Cancer Institute
As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.
All identified conflicts of interests have been resolved.
Faculty
G. Travis Clifton, MD has disclosed the following financial relationships: Parthenon Therapeutics - Employee, Stocks
Mihir Shah, MD, MSc, has disclosed no financial relationships.
Salma Jabbour, MD has disclosed the following financial relationship:Merck & Co. - Consultant, Contracted Research; IMX Medical - Consultant; Syntactx - Consultant; ASTRO - Speaker
Onkar Khullar, MD has disclosed no financial relationships
Howard Hochster, MD has disclosed the following financial relationship: Bayer - Consultant; Genentech - Consultant; Merck - Consultant; TRIGR - Consultant, Stocks; Processa - Consultant; Natera - Speaker
Planners, Reviewers, and Staff
Timothy Fitzgerald, MD, CME Committee Reviewer, has disclosed no financial relationships.
Ibrahim Sallam, MD, CME Committee Reviewer, has disclosed no financial relationships.
Krystine Hansen, CAE and Kelley Gazer, Society of Surgical Oncology, have disclosed no financial relationships.
Michelle Forcier, Natasha Mitchner, Lisa Keckich, Sara Brykalski, Nicolle Rochino, Vanessa Senatore, Amanda Kaczerski, Katlyn Cooper, Emily Bennett and Ritesh Kothari, Academy for Continued Healthcare Learning, have disclosed no financial relationships.
Patti Stella, CAE, CHCP, Director of Education, Society of Surgical Oncology, has disclosed the following financial relationships: Horizon Pharmaceutical PLC – Stocks; SPDR Biotech – Stocks.
The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.
This activity consists educational content, a self-assessment exam, and an evaluation. Learners must view the activity content, complete the self-assessment exam and achieve a minimum score of 75%. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Society of Surgical Oncology designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The SSO has approved this activity for up to 1 self-assessment credit which meets the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.
